The B cell-stimulating molecules, BAFF (B cell activating factor) and APRIL (a proliferation-
inducing ligand), are critical factors in the maintenance of the B cell pool and humoral …

One challenge in caring for patients with systemic lupus erythematosus (SLE) is a paucity of
approved therapeutics for treatment of the diverse disease manifestations. In the last 60 …

Patients affected with systemic lupus erythematosus (SLE) still display increased mortality
and decreased quality of life in respect to general population. The major determinant of poor …

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease presenting highly
heterogeneous clinical manifestations and multi-systemic involvement. Patients are …

Update on clinical trials in systemic lupus erythematosus : Current Opinion in
Rheumatology Update on clinical trials in systemic lupus erythematosus : Current Opinion …

Belimumab (Benlysta) is a fully-humanized monoclonal antibody that inhibits B-lymphocyte
stimulator (also known as B cell activating factor) and was approved by the US Federal Drug …

Systemic lupus erythematosus (SLE) is an autoimmune disease with a polymorphic
presentation. The variability in the clinical expression and severity of SLE makes new …

Objective: To study self-administration and pharmacokinetics (PK) of subcutaneous (SC)
belimumab in patients with systemic lupus erythematosus (SLE). Methods: Patients …

Introduction: Blisibimod is a potent and selective inhibitor of B cell activating factor (BAFF), a
mediator of differentiation, maturation and survival of B cells. It has a unique …

Introduction: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease
characterized by highly heterogeneous clinical manifestations and a multi systemic …